Please wait a minute...
文章检索
预防医学  2023, Vol. 35 Issue (11): 992-996    DOI: 10.19485/j.cnki.issn2096-5087.2023.11.017
  疾病监测 本期目录 | 过刊浏览 | 高级检索 |
2008—2022年崇川区疑似预防接种异常反应监测结果
顾红1, 侯晓艳2, 祁志刚1, 吴明1
1.南通市崇川区疾病预防控制中心免疫规划科,江苏 南通 226001;
2.南通市疾病预防控制中心,江苏 南通 226001
Surveillance of suspected adverse events following immunization in Chongchuan District from 2008 to 2022
GU Hong1, HOU Xiaoyan2, QI Zhigang1, WU Ming1
1. Department of Immunization Planning, Chongchuan District Center for Disease Control and Prevention, Nantong, Jiangsu 226001, China;
2. Nantong Center for Disease Control and Prevention, Nantong, Jiangsu 226001, China
全文: PDF(833 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 了解2008—2022年江苏省南通市崇川区疑似预防接种异常反应(AEFI)发生情况,为疫苗接种安全性评价提供依据。方法 通过中国免疫规划信息系统AEFI监测系统收集2008—2022年崇川区AEFI监测资料,包括AEFI病例的人口学信息、预防接种史、实验室检测资料、AEFI发病和临床资料;描述性分析2008—2022年崇川区AEFI发生特征和报告发生率。结果 2008—2022年崇川区AEFI报告发生率呈下降趋势(P<0.05),年均报告发生率为50.85/10万剂。免疫规划疫苗AEFI报告发生率为74.67/10万剂,高于非免疫规划疫苗的20.35/10万剂(P<0.05)。报告发生的AEFI以一般反应为主,1 937例,报告发生率为44.21/10万剂;异常反应274例,报告发生率为6.25/10万剂;偶合症17例,报告发生率为0.39/10万剂;无疫苗质量事故和接种事故报告。经皮下注射和肌内注射途径的疫苗AEFI报告发生率较高,分别为75.05/10万剂和47.40/10万剂;口服途径的报告发生率较低,为16.41/10万剂。AEFI报告发生率居前五位的疫苗为无细胞百白破b型流感嗜血杆菌(结合)联合疫苗(312.01/10万剂)、7价肺炎球菌多糖结合疫苗(292.14/10万剂)、乙脑灭活疫苗(248.37/10万剂)、ACYW135群脑膜炎球菌多糖疫苗(240.67/10万剂)和麻疹风疹联合减毒活疫苗(229.31/10万剂)。一般反应以发热、红肿和硬结等为主,1 878例占96.95%;异常反应以过敏性皮疹为主,241例占87.96%。91.34%的AEFI发生于接种后24 h内。AEFI报告3个月后随访,99.73%的病例痊愈。结论 2008—2022年崇川区AEFI报告发生率呈下降趋势。AEFI类型以一般反应为主,预后良好,疫苗接种安全性较高。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
顾红
侯晓艳
祁志刚
吴明
关键词 疑似预防接种异常反应监测疫苗    
AbstractObjective To investigate the incidence of suspected adverse events following immunization(AEFI) in Chongchuan District, Nantong City, Jiangsu Province from 2008 to 2022, so as to provide insights into safety assessment of vaccines. Methods The data on AEFI surveillance in Chongchuan District from 2008 to 2022 were collected through the National Immunization Program Information Management System of China, including demographics, history of vaccination, laboratory tests, incidence of AEFI and clinical characteristics. The epidemiological, clinical characteristics and reported incidence of AEFI were analyzed in Chongchuan District from 2008 to 2022 using a descriptive epidemiological method. Results The reported incidence of AEFI in Chongchuan District from 2008 to 2022 appeared a tendency towards a decline (P<0.05), and the annual average reported incidence was 50.85/105. The incidence of AEFI associated with vaccines included in the national immunization program was significantly higher than that caused by vaccines that were not included in the national immunization program (74.67/105 vs. 20.35/105, P<0.05). General reaction was the predominant type of AEFI (1 937 cases, 44.21/105), and there were 274 cases with abnormal reactions (6.25/105) and 17 cases with coincident syndromes (0.39/105); however, no vaccine quality or vaccination accidents occurred. A high incidence rate was seen in AEFI associated with vaccines administered by subcutaneous (75.05/105) and intramuscular injection (47.40/105), and a low incidence rate was found in AEFI associated with vaccines administered orally (16.41/105). The five highest reported incidence rates of AEFI were found for the combined diphtheria, tetanus, acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine (312.01/105), 7-valent pneumococcal polysaccharide-protein conjugate vaccine (292.14/105), inactivated Japanese encephalitis vaccine (248.37/105), Group ACYW135 meningococcal polysaccharide vaccine (240.67/105) and combined live vaccine for measles and rubella (229.31/105). The general reactions mainly included fever, redness and swelling and induration (1 878 cases, 96.95%), and abnormal reactions mainly included allergic skin rash (241 cases, 87.96%). In addition, 91.34% of AEFI occurred within 24 hours after vaccination, and 99.73% of cases with AEFI were cured during the 3-month follow-up. Conclusions The reported incidence of AEFI appeared a tendency towards a decline in Chongchuan District from 2008 to 2022. General reaction was the predominant type of AEFI, and all AEFI showed a good prognosis. The safety of vaccines was high in Chongchuan District from 2008 to 2022.
Key wordssuspected adverse event following immunization    surveillance    vaccine
收稿日期: 2023-07-31      修回日期: 2023-10-08      出版日期: 2023-11-10
中图分类号:  R186  
基金资助:中国肝炎防治基金会2020年度中国乙肝防控科研基金(YGFK20200038)
作者简介: 顾红,本科,副主任医师,主要从事免疫规划工作
通信作者: 侯晓艳,E-mail:369511306@qq.com   
引用本文:   
顾红, 侯晓艳, 祁志刚, 吴明. 2008—2022年崇川区疑似预防接种异常反应监测结果[J]. 预防医学, 2023, 35(11): 992-996.
GU Hong, HOU Xiaoyan, QI Zhigang, WU Ming. Surveillance of suspected adverse events following immunization in Chongchuan District from 2008 to 2022. Preventive Medicine, 2023, 35(11): 992-996.
链接本文:  
https://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2023.11.017      或      https://www.zjyfyxzz.com/CN/Y2023/V35/I11/992
[1] 张丽娜,李克莉,杜雯,等. 2019年中国疑似预防接种异常反应监测[J]. 中国疫苗和免疫,2021,27(4):438-445.
[2] 张丽娜,李克莉,杜雯,等. 2018年中国疑似预防接种异常反应监测[J]. 中国疫苗和免疫,2020,26(4):363-371.
[3] 张丽娜,李克莉,李燕,等. 2020年中国疑似预防接种异常反应监测[J]. 中国疫苗和免疫,2022,28(2):208-217.
[4] 侯晓艳,廉丽华,倪杰,等. 2008—2020年南通市疫苗接种安全性分析与评估[J]. 职业与健康,2022,38(19):2672-2677,2682.
[5] 吴瑛,李瑞平,高彩红.2010—2020年上海市奉贤区南桥镇疑似预防接种异常反应监测数据分析[J]. 职业与健康,2022,38(5):654-658.
[6] 杨菊,马紫妍,王洁,等. 2015—2021年郑州市二七区疑似预防接种异常反应监测结果分析[J]. 华南预防医学,2022,48(6):773-776.
[7] 王晓柳,汤元妃. 2018—2021年武义县疑似预防接种异常反应监测结果[J]. 预防医学,2022,34(11):1167-1171,1177.
[8] 杜哲群,胡洁,沈国初,等. 嘉兴市8月龄儿童接种MMR、MR疫苗疑似预防接种异常反应监测结果[J]. 预防医学,2020,32(11):1086-1090.
[9] 吴琳琳,刘捷宸,李智,等. 2011—2018年上海市含麻疹成分疫苗疑似预防接种异常反应监测分析[J]. 上海预防医学,2021,33(4):291-295.
[10] 沈金花,陈文花,顾士康,等. 2011—2016年松江区预防接种不良事件监测分析[J]. 现代预防医学,2018,45(10):1890-1894.
[11] 胡丽楠,李岩,郭爽,等. 2007—2019年哈尔滨市疑似预防接种异常反应监测分析[J]. 现代预防医学,2020,47(12):2258-2262.
[12] 张英,罗美玲. 长沙市儿童免疫规划疫苗延迟接种现状及影响因素分析[J]. 预防医学,2021,33(3):280-283.
[1] 徐艳平, 闫晓彤, 姚丁铭, 徐越, 张雪海, 孙洁, 徐锦杭. 浙江省中老年人肺炎疫苗接种意愿的影响因素研究[J]. 预防医学, 2025, 37(9): 881-885.
[2] 顾伟玲, 彭晗琪, 吕大兵, 富小飞, 亓云鹏, 谢亮, 向泽林. 2001—2024年嘉兴市血吸虫病和螺情监测结果分析[J]. 预防医学, 2025, 37(9): 897-902.
[3] 陈绍云, 曹思静, 霍泳琦, 谷超男, 严新凤, 于传宁. 龙华区伤害病例特征分析[J]. 预防医学, 2025, 37(9): 950-954,958.
[4] 王晓宇, 张志平, 董玉颖, 梁杰, 陈强. 老年人带状疱疹疫苗接种意愿的影响因素分析[J]. 预防医学, 2025, 37(8): 809-813.
[5] 孙强, 黄颖, 李小勇, 杨晨迎, 王思嘉. 2014—2023年宁波市老年伤害病例特征分析[J]. 预防医学, 2025, 37(8): 822-826,831.
[6] 赵志元, 郑俐敏. 我国人用狂犬病疫苗接种不良反应研究进展[J]. 预防医学, 2025, 37(7): 682-686.
[7] 孙玲, 刘元青, 刘新光, 张楠, 温婵, 郝建宗, 李梅. 河北省某儿童医院住院患儿多重耐药菌耐药性分析[J]. 预防医学, 2025, 37(6): 616-621.
[8] 黄阳梅, 沈旭娟, 谢董颖, 张琦, 郑子聪, 王勐. 小学生体重监测信息反馈干预的效果评价[J]. 预防医学, 2025, 37(6): 541-545.
[9] 田海艳, 李保军, 陈奕. 宁波市流行性腮腺炎突破病例分析[J]. 预防医学, 2025, 37(3): 292-295.
[10] 唐学雯, 白祎然, 苏颖, 龚黎明, 严睿, 朱瑶, 何寒青. 一例急性弛缓性麻痹病例检出疫苗衍生脊髓灰质炎病毒的流行病学调查[J]. 预防医学, 2025, 37(2): 178-180,188.
[11] 余朝彦, 洪斌, 吴小军, 王年伟, 高燕, 王杨凤. 阿坝藏族羌族自治州工作场所重点职业病危害因素监测结果[J]. 预防医学, 2025, 37(12): 1277-1281.
[12] 李依窈, 李小菊, 申小颖, 张宪琦, 赵莉, 张玉涵, 汪欣梦. 老年人接种流行性感冒疫苗的影响因素分析[J]. 预防医学, 2025, 37(1): 31-35.
[13] 杨旭, 王旭雯. 2015—2023年无锡市风疹流行特征[J]. 预防医学, 2025, 37(1): 65-68.
[14] 王苗玲, 童莺歌. 疫苗素养评价工具研究进展[J]. 预防医学, 2024, 36(9): 768-771.
[15] 王颖, 江媚, 华丽, 林玉幸. 海珠区14岁以下儿童水痘突破病例特征分析[J]. 预防医学, 2024, 36(6): 523-526.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed